

### Resignation of Chief Financial Officer

**Genetic Signatures Limited [ASX:GSS]** (“GSS” or “the Company”), a global molecular diagnostics company announces the resignation of Chief Financial and Operating Officer, and Joint Company Secretary, Karl Pechmann.

Since joining GSS in June 2023, Mr Pechmann has played a pivotal role in strengthening the Company’s financial management, operational performance, and corporate governance. His leadership has supported the Company’s ongoing transformation and has positioned the Company for future growth.

Mr Pechmann will depart the business on Friday, 30 January 2026. The Board has commenced a formal executive search process to identify a suitable successor, and interim arrangements will be put in place to ensure continuity of operations.

Allison Rossiter, CEO of Genetic Signatures, said “Karl’s dedication, professionalism, and unwavering commitment will leave a lasting legacy at Genetic Signatures. His ability to lead through challenging times and inspire those around him has been invaluable. On behalf of the Board and the entire team, I extend our deepest gratitude for his significant contributions and wish him every success as he embarks on the next exciting chapter of his career.”

– END –

#### **Announcement authorised by Genetic Signatures’ Board of Directors**

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us:

**Allison Rossiter**

**Chief Executive Officer**

[allison.rossiter@geneticsignatures.com](mailto:allison.rossiter@geneticsignatures.com)

T: +61 (0)2 9870 7580

**Karl Pechmann**

**Chief Financial Officer**

[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

#### **About Genetic Signatures Limited:**

Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures’ proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.